Multiple myeloma has become one of the most therapeutically dynamic malignancies in hematologic oncology, with patients now routinely receiving quadruplet induction regimens, maintenance therapy, and autologous stem cell transplant followed by years of surveillance. Each phase of this journey generates distinct administrative obligations—prior authorizations for expensive novel agents, REMS compliance for lenalidomide and pomalidomide, IMWG response documentation at every response assessment, and transplant coordination workflows. Virtual assistants (VAs) trained in myeloma clinic operations are providing the administrative backbone that allows these programs to scale without proportional staffing increases.
IMWG Response Criteria Documentation
The International Myeloma Working Group (IMWG) uniform response criteria—stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), and progressive disease (PD)—require systematic documentation of serum and urine protein electrophoresis results, free light chain ratios, bone marrow biopsy findings, and immunofixation results at each response assessment cycle. In practices managing 50 or more active myeloma patients, this documentation cycle generates continuous administrative work.
VAs can maintain the myeloma response tracking database, ensure lab results are available and documented before each restaging visit, calculate response category based on the practice's defined algorithm, and prepare structured response summary documents for the treating hematologist. This systematic approach also feeds the practice's clinical outcomes data, supporting quality reporting and tumor registry submissions.
Daratumumab and Lenalidomide Prior Authorization
Daratumumab-based regimens (DaraVRd, DaraRd, DaraPd) are now standard of care across multiple myeloma lines, but each authorization cycle requires current disease status documentation, prior therapy history, ECOG performance status attestation, and renal function data. Lenalidomide and pomalidomide, as REMS-restricted agents through the REVLIMID REMS and POMALYST REMS programs, require additional documentation—patient enrollment, prescriber enrollment, and pharmacy dispensing compliance.
According to the International Myeloma Foundation's 2025 Patient Survey, 44% of myeloma patients reported experiencing at least one therapy delay due to prior authorization or REMS compliance issues. VAs can manage both authorization streams simultaneously—submitting PA requests to commercial and Medicare Part D plans, tracking REMS enrollment status for each patient, and ensuring prescription renewals are initiated before the coverage window closes.
CRAB Criteria Monitoring Coordination
CRAB criteria—hyperCalcemia, Renal insufficiency, Anemia, and Bone lesions—define end-organ damage in myeloma and trigger both treatment initiation decisions and active disease monitoring. VAs can maintain a CRAB monitoring dashboard for patients on active surveillance or maintenance therapy, tracking serial creatinine values, hemoglobin trends, calcium levels, and imaging schedules for bone lesion assessment.
When values approach CRAB thresholds, the VA can flag the case for expedited provider review before the scheduled visit, enabling earlier intervention. This proactive monitoring role is particularly valuable for smoldering myeloma patients under surveillance who may not have frequent scheduled appointments.
Autologous Stem Cell Transplant Coordination
Autologous HSCT remains a standard consolidation strategy for eligible myeloma patients. The pre-transplant coordination workflow includes stem cell mobilization scheduling (G-CSF ± plerixafor), apheresis unit coordination, collection adequacy confirmation, product cryopreservation logistics, insurance authorization for the transplant admission, and pre-transplant evaluation package assembly. Post-transplant, the VA coordinates Day 30 and Day 100 bone marrow biopsies, MRD testing logistics, and maintenance therapy initiation scheduling.
Clinics looking to build out myeloma administrative support with trained healthcare VAs can explore options at Stealth Agents.
Maintaining Continuity Across Long Treatment Journeys
Myeloma patients often remain under active management for years, cycling through multiple lines of therapy with distinct authorization, monitoring, and coordination requirements at each transition. VAs who maintain longitudinal administrative continuity for myeloma patients—knowing each patient's therapy history, authorization status, and upcoming milestone—provide a level of care coordination that improves both efficiency and patient experience in a disease that demands it.
Sources
- International Myeloma Foundation. 2025 Myeloma Patient Survey: Access, Treatment, and Support. North Hollywood, CA: IMF; 2025.
- Kumar SK, et al. "IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma." Leukemia. 2016;30(8):1succinctly–1854. [Criteria active; updated guidance 2024.]
- FDA. REVLIMID REMS Program: 2025 Annual Compliance Report. Silver Spring, MD: FDA; 2025.
- American Society of Hematology. 2025 Myeloma Practice Guidelines Update. Washington, DC: ASH; 2025.